The Kislinger Laboratory is located at the Princess Margaret Cancer Research Tower of the Princess Margaret Cancer Centre, the largest oncology treatment and research facility in Canada. The major goal of our lab is to apply proteomics technologies to cancer and cardiovascular research. Our research interests include technology development, using the latest generation of mass spectrometry instrumentation, basic cell biology and translational cancer research.
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Nat Cell Biol. 2016 Jun 20;
J Cell Sci. 2016 May 13;
Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
PLoS One. 2016;11(4):e0154074
Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.
Expert Rev Proteomics. 2016 Mar 12;
Clin Chem. 2016 Jan 27;
Evolutionarily conserved intercalated disc protein Tmem65 regulates cardiac conduction and connexin 43 function.
Nat Commun. 2015;6:8391
A Genome Scale Screen for Mutants with Delayed Exit from Mitosis: Ire1-Independent Induction of Autophagy Integrates ER Homeostasis into Mitotic Lifespan.
PLoS Genet. 2015 Aug;11(8):e1005429
Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome.
Proteomics Clin Appl. 2009 Mar;3(3):347-58
Semi-supervised Learning Predicts Approximately One Third of the Alternative Splicing Isoforms as Functional Proteins.
Cell Rep. 2015 Jul 1;
Senior Scientist, Princess Margaret Cancer Centre